Life-span extension therapy: NR2F2 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 9/June/2015, 11.08 am

Molecular therapy for Hyperglycemia & T2DM: Antrodia salmonea increases the expression of AMPK(5′ adenosine monophosphate-activated protein kinase), decreases gluconeogenesis and fasting glucose level via up regulation of its target gene, 9/June/2015, 8.31 am
June 9, 2015
Molecular therapy for metastatic breast cancer: BMP4 blocks bone metastasis of mammary cancer via down regulation of its target gene, 9/June/2015, 11.55 am
June 9, 2015
Show all

A recent study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 )by Prof Dominic J. Withers, Dr. Selman C and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports that:  Life-span extension therapy: NR2F2 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Life-span extension therapy: NR2F2 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 9/June/2015, 11.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study suggests that NR2F2, by increasing the expression of its target gene, it may decrease the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase). Thereby, it may promote resistance to bone, immune, and motor dysfunction.   Thus, pharmacological formulations encompassing “NR2F2  activators may be used to extend the life span of an individual.

Undisclosed information: How NR2F2 decreases the expression of p70S6 Kinase

Comments are closed.